Ameriprise
CRBP icon

Ameriprise’s Corbus Pharmaceuticals CRBP Stock Holding History

Ameriprise’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-135,730
Closed -$1.1M – 4096
2025
Q4 		$1.1M Buy
135,730
+66,105
+95% +$816K ﹤0.01% 3283
2025
Q3 		$881K Buy
+69,625
New +$662K ﹤0.01% 3419
2024
Q4 		– Sell
-10,382
Closed -$214K – 4096
2024
Q3 		$214K Sell
10,382
-1,032
-9% -$52.8K ﹤0.01% 3730
2024
Q2 		$516K Buy
+11,414
New +$480K ﹤0.01% 3405
2022
Q2 		– Sell
-425
Closed -$7K – 3903
2022
Q1 		$7K Sell
425
-600
-59% -$7.95K ﹤0.01% 3921
2021
Q4 		$19K Buy
1,025
+543
+113% +$14.7K ﹤0.01% 3928
2021
Q3 		$15K Sell
482
-14
-3% -$552 ﹤0.01% 3839
2021
Q2 		$27K Sell
496
-22
-4% -$1.22K ﹤0.01% 3867
2021
Q1 		$31K Sell
518
-57
-10% -$3.75K ﹤0.01% 3816
2020
Q4 		$21K Sell
575
-1,123
-66% -$42K ﹤0.01% 3744
2020
Q3 		$91K Buy
1,698
+161
+10% +$29.2K ﹤0.01% 3649
2020
Q2 		$387K Buy
+1,537
New +$311K ﹤0.01% 3282

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise's CRBP Position: Q1 2026 in Review

Ameriprise sold out of Corbus Pharmaceuticals (CRBP) in Q1 2026, closing a stake of 135,730 shares — an estimated $1.1M sold.

Ameriprise first reported a position in CRBP in Q2 2020 and held it in 12 quarters. The position peaked at $1.1M in Q4 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Ameriprise reported no remaining Corbus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Ameriprise sold 135,730 Corbus Pharmaceuticals shares in Q1 2026, an estimated $1.1M.
  • Ameriprise first reported a position in Corbus Pharmaceuticals in Q2 2020 and held it in 12 quarters.
  • Ameriprise's Corbus Pharmaceuticals position peaked at $1.1M in Q4 2025.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.